Skip to Main Content

Author Details

Joshua Chuck Harrell
Virginia Commonwealth University
2002
71
34
Nathan Sheffield (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37067481excluderanges: exclusion sets for T2T-CHM13, GRCm39, and other genome assemblies.Bioinformatics2023
37160896Publisher Correction: Rewiring of the 3D genome during acquisition of carboplatin resistance in a triple-negative breast cancer patient-derived xenograft.Sci Rep2023
37012431Rewiring of the 3D genome during acquisition of carboplatin resistance in a triple-negative breast cancer patient-derived xenograft.Sci Rep2023
37370789Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer.Cancers (Basel)2023
34815360Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer.Mol Cancer Ther2022
36712364Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models.PNAS Nexus2022
36482068Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer.Sci Rep2022
35312280Single-Molecule Sensor for High-Confidence Detection of miRNA.ACS Sens2022
34188118Serine residues 726 and 780 have nonredundant roles regulating STAT5a activity in luminal breast cancer.Sci Rep2021
33880552Chromatin conformation capture (Hi-C) sequencing of patient-derived xenografts: analysis guidelines.Gigascience2021
33675501Breast cancer liver metastasis: current and future treatment approaches.Clin Exp Metastasis2021
33589921Prolactin Drives a Dynamic STAT5A/HDAC6/HMGN2 Cis-Regulatory Landscape Exploitable in ER+ Breast Cancer.Endocrinology2021
33772010The human intermediate prolactin receptor is a mammary proto-oncogene.NPJ Breast Cancer2021
34628286Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer.Transl Oncol2021
32845995The Roles of Autophagy and Senescence in the Tumor Cell Response to Radiation.Radiat Res2020
32001757Identification of synergistic drug combinations using breast cancer patient-derived xenografts.Sci Rep2020
31938954The utility of the "Glowing Head" mouse for breast cancer metastasis research.Clin Exp Metastasis2020
32576280New generation breast cancer cell lines developed from patient-derived xenografts.Breast Cancer Res2020
30819233The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.Breast Cancer Res2019
30841919Separation of breast cancer and organ microenvironment transcriptomes in metastases.Breast Cancer Res2019
31069566Quantitative assessment of breast cancer liver metastasis expansion with patient-derived xenografts.Clin Exp Metastasis2019
29620732Erratum: Asparagine bioavailability governs metastasis in a model of breast cancer.Nature2018
30315000Sphingosine kinase 1 activation by estrogen receptor α36 contributes to tamoxifen resistance in breast cancer.J Lipid Res2018
30613814Live Cell Mass Accumulation Measurement Non-Invasively Predicts Carboplatin Sensitivity in Triple-Negative Breast Cancer Patient-Derived Xenografts.ACS Omega2018
29414946Asparagine bioavailability governs metastasis in a model of breast cancer.Nature2018
29532339Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer.Breast Cancer Res Treat2018
28972041PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.Clin Cancer Res2017
29176653Estrogen induces c-Kit and an aggressive phenotype in a model of invasive lobular breast cancer.Oncogenesis2017
28972043Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.Clin Cancer Res2017
26919310Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.Cell Cycle2016
27358110HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth.Mol Cancer Res2016
25361981Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.Ann Oncol2015
26365194Sox10 Regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells.Cell Rep2015
27656679αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis.NPJ Breast Cancer2015
26687066The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p.Nat Commun2015
26080861Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours.Nat Commun2015
26105795CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.Breast Cancer Res Treat2015
25855289A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis.Nature2015
23975155Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis.Clin Exp Metastasis2014
25339353Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models.Cancer Res2014
25358638Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3.Breast Cancer Res2014
24567196Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures.Breast Cancer Res Treat2014
24463450Taxonomy of breast cancer based on normal cell phenotype predicts outcome.J Clin Invest2014
24257808Identification of a stable molecular signature in mammary tumor endothelial cells that persists in vitro.Angiogenesis2014
23247610Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features.Breast Cancer Res Treat2013
24162158Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.Breast Cancer Res Treat2013
24220145Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts.Genome Biol2013
21671017Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.Breast Cancer Res Treat2012
22765220Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.Breast Cancer Res2012
22821401Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.Breast Cancer Res Treat2012
  • 1 - 50 of 71

Recommended Authors

Martin Sj??str??m
University of California-San Francisco
Career Start Year 2013
Number of shared co-authors 0
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Bora Lim
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 1
Rut Klinger
UCD Conway Institute, University College Dublin
Career Start Year 2006
Number of shared co-authors 0
Christina Yau
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 1
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 0
Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2002
Number of shared co-authors 2
Britta Weigelt
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 2
Saravut J Weroha
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 1
Massimo Cristofanilli
Weill Cornell School of Medicine
Career Start Year 1998
Number of shared co-authors 0
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 1
Cecilia Williams
Karolinska Institutet
Career Start Year 1997
Number of shared co-authors 1
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 2
Hai Hu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 1
William M Gallagher
All-Island Cancer Research Institute, UCD Conway Institute, University College Dublin
Career Start Year 1996
Number of shared co-authors 2
Michael T Lewis
Baylor College of Medicine
Career Start Year 1996
Number of shared co-authors 2
Alexander D Borowsky
University of California Davis Health
Career Start Year 1995
Number of shared co-authors 0
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 2
Susan J Done
University Health Network
Career Start Year 1994
Number of shared co-authors 0
Paul N Span
Radboud University Medical Center
Career Start Year 1993
Number of shared co-authors 2
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 2
Kornelia Polyak
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
Career Start Year 1991
Number of shared co-authors 1
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 4
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 1
Jos Jonkers
Oncode Institute, Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 2
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 1
Laura J Van't Veer
University of California San Francisco
Career Start Year 1984
Number of shared co-authors 1
Christopher C Benz
Buck Institute for Research on Aging
Career Start Year 1977
Number of shared co-authors 4
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Career Start Year 1973
Number of shared co-authors 1

Collaborators

Charles M Perou
Co-authored papers 21
Mikhail G Dozmorov
Virginia Commonwealth University
Co-authored papers 11
Amy L Olex
Virginia Commonwealth University
Co-authored papers 10
Lisa A Carey
Co-authored papers 4
Cheng Fan
Co-authored papers 4
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Co-authored papers 3
Jason Reed
Department of Physics Virginia Commonwealth University Richmond VA USA.
Co-authored papers 3
Gregory J Hannon
Co-authored papers 3
Melissa A Troester
Co-authored papers 3
Nathan Sheffield (CM4AI)
University of Virginia
Co-authored papers 2
Carey K Anders
Co-authored papers 2
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Co-authored papers 2
Barbro Linderholm
Sahlgrenska University Hospital
Co-authored papers 2
Joan S Brugge
Co-authored papers 1
Dean Billheimer
Co-authored papers 1
Jonathan D Ogata
Virginia Commonwealth University
Co-authored papers 1
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 1
Andrea L Richardson
Co-authored papers 1
David C Boyd
Virginia Commonwealth University
Co-authored papers 1
Cyril H Benes
Co-authored papers 1
Myles Brown
Co-authored papers 1
Katarzyna M Tyc
and Massey Cancer Center, Virginia Commonwealth University
Co-authored papers 1
Fathi Elloumi
Inc., Frederick National Laboratory for Cancer Research
Co-authored papers 1
Christopher Ryan Miller
University of Illinois at Urbana-Champaign
Co-authored papers 1
Donald C Allred
Co-authored papers 1
Jerry Usary
Co-authored papers 1
Michael I Love
University of North Carolina at Chapel Hill
Co-authored papers 1
Christopher P Crum
Co-authored papers 1
Eric S Davis
University of North Carolina at Chapel Hill
Co-authored papers 1
Sandro Santagata
Co-authored papers 1
Release 1.2